CONVINCE trial reveals the effect of long-term colchicine on recurrent stroke and cardiovascular events

FHS
May 16, 2024
5:39 pm

In the international CONVINCE trial, presented today (15 May 2024) at the European Stroke Organisation Conference (ESOC) 2024, anti-inflammatory treatment with long-term colchicine did not reduce rates of recurrent stroke and cardiovascular events in patients with non-cardioembolic stroke in the primary intention-to-treat analysis.

M1 Kliniken AG (von First Berlin Equity Research GmbH) – Biotech Investments

Original-Research: M1 Kliniken AG – von First Berlin Equity Research GmbH Einstufung von First Berlin Equity Research GmbH zu M1 Kliniken AG Unternehmen: M1 Kliniken

December 21, 2023

Uveitis History Linked to Recurrence After COVID Vaccination

People with a history of uveitis were more likely to experience recurrences of the potentially dangerous eye inflammation after vaccination against COVID-19, a retrospective population-based

April 26, 2024

Novo Nordisk stops trial of Ozempic in kidneys as interim analysis shows success – Pharmaceutical Technology

According to GlobalData, Novo Nordisk’s Wegovy (semaglutide) (indicated for obesity) and Ozempic are forecast to reach sales of $8.1bn and $2.1bn by 2031, respectively. Credit:

October 17, 2023

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.